Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Lancet Haematol. 2019 Mar;6(3):e132–e143. doi: 10.1016/S2352-3026(18)30221-7

Figure 2C:

Figure 2C:

Chronic GVHD Requiring Systemic Immunosuppression

Control vs. Tac/MTX/Bortezomib at 12 mo-p=0.23

Control vs. Tac/MTX/Maraviroc at 12 mo-p=0.50

Control vs. Tac/MMF/Cy at 12 mo-p=0.0081